| 15.58 0.95 (6.49%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.32 | 1-year : | 21.4 |
| Resists | First : | 15.68 | Second : | 18.32 |
| Pivot price | 12.36  |
|||
| Supports | First : | 8.93 | Second : | 4.76 |
| MAs | MA(5) : | 15.12 |
MA(20) : | 11.52 |
| MA(100) : | 7.89 |
MA(250) : | 7.67 |
|
| MACD | MACD : | 1.4 |
Signal : | 1 |
| %K %D | K(14,3) : | 94.2 |
D(3) : | 94  |
| RSI | RSI(14): 68.4 |
|||
| 52-week | High : | 15.68 | Low : | 1.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ REPL ] has closed below upper band by 23.8%. Bollinger Bands are 130.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 15.62 - 15.72 | 15.72 - 15.81 |
| Low: | 14.29 - 14.39 | 14.39 - 14.49 |
| Close: | 15.41 - 15.57 | 15.57 - 15.73 |
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Tue, 18 Aug 2026
Replimune Soars Over 120% as FDA Panel Backs Melanoma Therapy Ahead of August Decision - finance.biggo.com
Tue, 18 Aug 2026
Replimune Group (NASDAQ:REPL) Shares Up 5.2% - What's Next? - MarketBeat
Tue, 18 Aug 2026
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Tue, 18 Aug 2026
Quantinno Capital Management LP Increases Stock Position in Replimune Group, Inc. $REPL - MarketBeat
Mon, 17 Aug 2026
REPL DEADLINE: Levi & Korsinsky Reminds Replimune Group, - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 84 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 118.9 (%) |
| Shares Short | 23,650 (K) |
| Shares Short P.Month | 22,890 (K) |
| EPS | -3.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.1 % |
| Return on Equity (ttm) | -107.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -280 (M) |
| Levered Free Cash Flow | -172 (M) |
| PE Ratio | -4.61 |
| PEG Ratio | 0 |
| Price to Book value | 7.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|